ArticleThe New England journal of medicine2016
I-SPY 2--Toward More Rapid Progress in Breast Cancer Treatment.
Article in The New England journal of medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- Trial
- Comparison of overall survival and disease-free survival for breast-conserving surgery and mastectomy in breast cancer patients receiving neoadjuvant therapy: a matched case-control study from two institutions.Frontiers in oncology · 2025Article
- Implementation of statistical features of a Bayesian two-armed responsive adaptive randomization trial with post hoc analysis of time trend drift.Journal of biopharmaceutical statistics · 2025Article
- A Strategy Utilizing Protein-Protein Interaction Hubs for the Treatment of Cancer Diseases.International journal of molecular sciences · 2023Review
- Rational combinations of targeted cancer therapies: background, advances and challenges.Nature reviews. Drug discovery · 2023Review
- Neoadjuvant therapy with doxorubicin-cyclophosphamide followed by weekly paclitaxel in early breast cancer: a retrospective analysis of 200 consecutive patients treated in a single center with a median follow-up of 9.5 years.Breast cancer research and treatment · 2022Article
- Persistent EGFR/K-RAS/SIAH pathway activation drives chemo-resistance and early tumor relapse in triple-negative breast cancer.Cancer drug resistance (Alhambra, Calif.) · 2022Review
- Clinical trial design during and beyond the pandemic: the I-SPY COVID trial.Nature medicine · 2022Article
- Master Protocols for Precision Medicine in Oncology: Overcoming Methodology of Randomized Clinical Trials.Life (Basel, Switzerland) · 2021Review
- Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer.NPJ breast cancer · 2021Article
- The Bayesian Design of Adaptive Clinical Trials.International journal of environmental research and public health · 2021Review
- Disease-free and overall survival after neoadjuvant chemotherapy in breast cancer: breast-conserving surgery compared to mastectomy in a large single-centre cohort study.Breast cancer research and treatment · 2021Article
- A manifesto for the future of ICU trials.Critical care (London, England) · 2020Article
- Review
- Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis.Clinical cancer research : an official journal of the American Association for Cancer Research · 2020Article
- Neoadjuvant Chemotherapy for Breast Cancer: Past, Present, and Future.Breast cancer : basic and clinical research · 2020Review
- Precision medicine and actionable alterations in lung cancer: A single institution experience.PloS one · 2020Article
- Bayesian clinical trials at The University of Texas MD Anderson Cancer Center: An update.Clinical trials (London, England) · 2019Article
- Prior to Initiation of Chemotherapy, Can We Predict Breast Tumor Response? Deep Learning Convolutional Neural Networks Approach Using a Breast MRI Tumor Dataset.Journal of digital imaging · 2019Article
- The FNIH Biomarkers Consortium embraces the BEST.Nature reviews. Drug discovery · 2019Article
Corrections and comments
- Comment on
- Comment on
Authors and funding
2 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
27406352What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.